MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing
Fig 2
Medicinal chemistry strategy and overview of expansive SAR campaign.
Modifications evaluated changes to the periphery of the ribose core, including 4′, 2′, and nucleobase positions, as well as replacement of the ribose core itself. SAR, structure–activity relationship.